Abstract
Abstract: Cardiac amyloidosis is a poorly understood cause of heart failure and is often undiagnosed. Recent advances in diagnostic testing and understanding of the disease have enhanced the ability of clinicians to detect this disease and provide patients with appropriate treatment. This article shares important information to help clinicians better understand transthyretin amyloidosis, including discussion on pathophysiology, diagnosis, prognosis, and management.